 Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 IL-2 INDUKINE molecule, in combination with KEYTRUDA pembrolizumab as a treatment for patients with solid tumors Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 IL-2 INDUKINE molecule, in combination with KEYTRUDA pembrolizumab as a treatment for patients with solid tumors 